Eslon Medical Receives Ethics Committee Approval to Add a Second Site to its Ongoing Clinical Trial of Hemopurifier® to Treat Severe COVID-19 in India

San Diego, May 22, 2023 /PRNewswire/ — Acelon Medical, Inc. (Nasdaq: AEMD), a medical therapeutics company focused on developing products for the diagnosis and treatment of cancer and life-threatening infections, today announced that its Ethical Review Board (ERB) ) has received approval from the U.S. government.Maulana Azad Medical College (MAMC), his second facility for ongoing clinical trials of Aethlon’s blood purifier® to treat severe novel coronavirus disease (COVID-19) India.

MAMC was founded in 1958, New Delhi, India. MAMC partnered with universities Delhi It is operated by Delhi government.

“We continue to see cases of COVID-19 requiring hospitalization. India. The addition of MAMC as a second quality clinical site may improve enrollment of patients with severe infections requiring ICU care.” Stephen LaRosaM.D., Chief Medical Officer of Acelon Medical.

Clinical trial of blood purifier for SARS patients by Eslon MedicalCoV-2 (or COVID-19) admitted to the ICU with severe or life-threatening illness is designed to enroll up to 15 patients in up to 3 centers for the entire period. India. The first site for the ongoing trial is Medanta His Medicity Hospital in Gurgaon. Indiais still open for registration, and one patient has been treated so far.

About Aethlon and blood purifiers®

Acelon Medical is a medical treatment company focused on developing blood purifiers, clinical-stage immunotherapy devices designed to combat cancer and life-threatening viral infections. Human studies have demonstrated that blood purifiers utilize a unique lectin-based technology to remove life-threatening viruses and harmful exosomes from the blood. This action has potential applications in cancer, where exosomes may promote immunosuppression and metastasis, as well as in life-threatening infections.

Blood purifiers are US Food and Drug Administration (FDA)-designated breakthrough devices in patients with advanced or metastatic cancer who are refractory to or intolerant of standard treatments, and exosomes have been shown to affect It is intended for the treatment of patients with certain cancer types. It is involved in the onset and exacerbation of diseases. The blood purifier also received FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses not addressed by approved therapies.

For additional information, please visit

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. “may”, “believe”, “anticipate”, “expect”, “intend”, “plan”, “predict”, “plan”, “predict”, “estimate”, ” Descriptive expressions including words such as “potentially” constitute forward-looking statements. Such forward-looking statements involve significant risks and uncertainties and actual results may differ materially from those anticipated in the forward-looking statements. These forward-looking statements are based on Acelon’s current expectations and include assumptions that may never materialize or prove to be inaccurate. Factors that may contribute to such differences include, but are not limited to, our ability to enroll patients in clinical trials. India, our ability to obtain timely FDA approval of new GNA suppliers, our ability to successfully treat patients under emergency use pathways, our ability to successfully complete the development of blood purification devices, and additional funding Our ability to procure, and our ability to expand clinical trials into other areas of cancer and other potential risks. The preceding list of risks and uncertainties is illustrative, but not exhaustive. Other factors that could cause results to differ materially from those anticipated in the forward-looking statements are set forth in our Annual Report on Form 10-K for the year ended under the caption “Risk Factors.” I’m here. March 31, 2022, and in our other filings with the Securities and Exchange Commission, including our quarterly report on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date they are made. We do not intend, and assume no obligation, to update this information to reflect future events or circumstances, except as required by law.

Company contact:
Jim Frakes
Acelon Medical Co., Ltd.
[email protected]

Investor contact:
Susan Noonan
SA Noonan Communications LLC
[email protected]

Source: Aethlon Medical, Inc.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *